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Abstract
We hypothesized that inhibiting molecules that mediate the adaptation response to cellular stress
can antagonize the resistance of pancreatic cancer cells to chemotherapeutic drugs. Toward this
end, here, we investigated how VMP1, a stress-induced autophagy-associated protein, modulate
stress responses triggered by chemotherapeutic agents in PDAC. We find that VMP1 is
particularly overexpressed in poorly differentiated human pancreatic cancer. Pharmacological
studies show that drugs that work, in part, via the endoplasmic reticulum stress response, induce
VMP1 expression. Similarly, VMP1 is induced by known endoplasmic reticulum stress activators.
Genetic inactivation of VMP1 using RNAi-based antagonize the pancreatic cancer stress response
to antitumoral agents. Functionally, we find that VMP1 regulates both autophagy and
chemotherapeutic resistance even in the presence of chloroquin, ATG5 or Beclin 1 siRNAs, or a
Beclin 1-binding VMP1 mutant. In addition, VMP1 modulates endoplasmic reticulum stress
independently of its coupling to the molecular and cellular autophagy machinery. Preclinical
studies demonstrate that xenografts expressing an inducible and tractable form of VMP1 show
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increased resistance to the gemcitabine treatment. These results underscore a novel role for VMP1
as a potential therapeutic target for combinatorial therapies aimed at sensitizing pancreatic cancer
cells to chemotherapeutic agents as well as provide novel molecular mechanisms to better
understand this phenomenon.
Introduction
VMP1, also known as TMEM49, was initially identified by our laboratory as a stress-
inducible gene in organs affected by acute inflammatory responses (Dusetti et al., 2002) or
transient ischemic injury. Subsequent, studies demonstrated that basal levels of VMP1
expression are a characteristic of the homeostatic state of many healthy tissues (Dusetti et
al., 2002). Careful structural-functional studies reveal that VMP1 is a transmembrane
protein with six hydrophobic regions, which allows it to locate to the intracellular
membranes of the endoplasmic reticulum (ER) and the Golgi apparatus (Dusetti et al.,
2002). In these organelles, VMP1 appear to be necessary for the endoplasmic reticulum
integrity as VMP1 deficient cells display pleiotropic defects in the secretory pathways and
organelle biogenesis (Calvo-Garrido et al., 2008). Forced expression of the VMP1/EGFP
fusion protein promotes the formation of intracytoplasmatic vacuoles in which VMP1/EGFP
is integrated into the membranes of these vacuoles (Dusetti et al., 2002). More recently,
these vacuoles have been identified to be autophagosomes (Ropolo et al., 2007) and the
mechanistic role of VMP1 as a regulator of autophagy established (Calvo-Garrido and
Escalante, 2010; Itakura and Mizushima, 2010; Lo Re et al., 2012; Ropolo et al., 2007; Tian
et al., 2010; Vaccaro et al., 2008), including in a specific form of autophagy named
zymophagy (Grasso et al., 2011). The subsequent discovery that VMP1 is both structurally
and functionally conserved in a wide range or organisms suggests that processes supported
by this protein have undergone evolutionary pressure to maintain homeostasis from
caenorhabditis elegans to human. Besides, it association to ER, Golgi, and autophagosomes,
VMP1 associates to the plasma membrane in several cell types where it interacts with the
tight junction protein Zonula Occludens-1 protein (Sauermann et al., 2008) to help support
tight junction formation and cell-cell contacts. Altogether, these data strongly suggest that
VMP1 is a versatile protein, which is required to maintain the integrity and function of many
membranous organelles in an evolutionarily conserved manner.
In the current study, we sought to further explore the biological significance of the
association of VMP1 to altered endoplasmic reticulum functions that characterize certain
human diseases, with a specific focus on pancreatic cancer. Key investigations, particularly
performed during the last two decades, have advanced our knowledge of the defined genetic
alterations which underly pancreatic cancer development, although the irreversible nature of
these mutations has hindered the development of either effective diagnosis or therapy.
Surgery is the most effective treatment but the mean life expectancy of the 15–20% of
patients who present with resectable tumor is only 15–18 months (Sultana et al., 2007). Even
for patients who are qualified for surgery, aggressive metastasis highly resistant to
conventional chemotherapy and radiation therapy often occurs after the operation.
Therefore, prognosis of pancreatic cancer is very poor, and the incidence almost equals with
the mortality rate, with a 5-year survival of less than 3–4%. Patients with locally advanced
Gilabert et al. Page 2
J Cell Physiol. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
disease have 6–10 months of median survival, and patients with metastatic disease only have
3–6 months of median survival (O’Reilly, 2009). Chemotherapy and radiotherapy offer
limited benefit in metastatic disease and in adjuvant setting for patients undergoing surgery
(Burris et al., 1997). Remarkably, however, the molecular mechanisms by which PDAC
cells become resistant remain poorly known. Thus, our laboratory have devoted significant
efforts to understand how these cells acquire their highly resistant phenotype and to find
novel mechanisms which can serve as targets for developing novel therapies to fight this
dismal disease. In this regard, studies on the effects of ER stress on cancer have recently
elicited significant attention since this response results in reduced protein translation,
increased chaperone activity, and ultimately lead to apoptotic cell death. In fact, functional
alterations in the endoplasmic reticulum (ER) deploy a distinct signaling network that
coordinates adaptive and apoptotic responses. Accumulating evidence has implicated
prolonged ER stress in the development and progression of many diseases, including cancer
(Hersey and Zhang, 2008; Koumenis, 2006; Li and Lee, 2006; Ozcan and Tabas, 2012).
Furthermore, a large body of literature indicates that many chemotherapeutic drugs, work at
least in part, by eliciting an ER response that contributed to tumoral cell death (Denmeade
and Isaacs, 2012; Herr and Debatin, 2001; Schonthal et al., 2011). Consequently, this data
raises the possibility that manipulation of the ER stress using small drugs may contribute to
the development of combinatorial therapies aimed at sensitizing PDAC cells to
chemotherapeutic agents.
In this article, we report that VMP1 is overexpressed in human pancreatic cancer, which are
associated with poor prognosis. Both cellular and in vivo assays demonstrate that VMP1 is
inducible by several endoplasmic reticulum stressors in pancreatic cancer cells. Moreover,
we demonstrate that VMP1 overexpression results in increased resistance to anticancer
drugs using well-characterized cellular and preclinical animal models of pancreatic cancer.
Mechanistically, we show that VMP1 overexpression is downstream of the ATF6 pathway,
a well-characterized regulator of ER stress in many cell systems. Therefore, our
observations in human pancreatic cancer when combined with studies in cell and animals
reveal for the first time a role for VMP1 as a modifier of the response of tumoral cells to
chemotherapeutic drugs, at least in part, due to its participation in ER stress pathways. We
believe that this new knowledge must be taken into consideration for the design and
evaluation of studies aimed at developing therapeutic interventions used in the management
of this malignant disease.
Material and Methods
Cell culture and viability
MiaPaCa2, Panc1 and HeLa cells were cultured in DMEM containing 10% heat-inactivated
fetal bovine serum (FBS). BxPc3 was cultured in RPMI 1640 containing 10% heat-
inactivated FBS, 2 mmol/L glutamine. Cell viability was determined using the CellTiter 96
Aqueous One Solution Reagent (Promega, Charbonnières-les-Bains, France) or Countess™
cell counter (Invitrogen) according to the instructions of the manufacturer.
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Transfections
Seventy-five percent confluent MiaPaCa2, Panc1 or HeLa cells were transfected with the
different small interfering RNAs (siRNA) using the X-tremeGENE siRNA Transfection
Reagent (Roche, Basel, Switzerland) according to the instructions of the manufacturer.
Twenty-four hours after transfection, cells were trypsinized and seeded at a density of
5,000/cm2. Transfection efficiency was monitored using a control fluorescent siRNA
(Qiagen, Hilden, Germany).
RNA interference
Double-stranded RNA duplexes corresponding to human VMP1 (5′-
r(GGCAGAAUAUUGUCCUGUGdTdT), ATF6 (siATF6; 5′-
r(GAGUUGUCUGUGUGAUGAUAGUAdTdT), human Beclin 1 (siBeclin1; 5′-
r(CAGUUUGGCACAAUCAAUAdTdT), human Atg5 (siATG5; 5′-
r(GCAACUCUGGAUGGGAUUGdTdT), and a nontargeted control (5′-
UUCUCCGAACGUGUCACGUdTdT) were purchased from Qiagen (Hilden, Germany).
Quantitative Real-Time Reverse Transcription PCR (qRT-PCR)
Total cellular RNA was isolated using the TRIzol protocol (Invitrogen, Cergy Pontoise,
France) and cDNAs were prepared from 1 μg total RNA using ImProm-II kit (Promega,
Charbonnières-les-Bains, France) following the manufacturer’s instructions. Quantitative
PCR was performed in a LightCycler (Roche Diagnostics, Meylan, France) using the SYBR
Premix Ex Taq (Takara Bio, Lonza, Levallois-Perret, France). The following sense and
antisense primers were used to amplify human VMP1 (sense, 5′-
TATGCCAAACGAATCCAGCAG-3′, and antisense, 5′-
CCAGTCTGTTGCAAGTTTGCTG-3′); the amplicon size is 313 bp. For ATF6 the forward
primer was 5′-GATAGACACTTATTACCACC-3′ and the reverse was 5′-
GGGTAGTCTAGTATTGTTTCC-3′; the amplicon size is 281 bp. For CHOP, the forward
primer was 5′-ATGAGGACCTGCAAGAGGTCC-3′ and the reverse was 5′-
TCCTCCTCAGTCAGCCAAGC-3′; the amplicon size is 136 bp. For GRP78, the forward
primer was 5′-GTTCTTGCCGTTCAAGGTGG-3′ and reverse was 5′-
TGGTACAGTAACAACTGCATG-3′; the amplicon size is 181 bp. For human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), used as a reference, the forward
primer was 5′-GGGAAGCTCACTGGCATGGCCTTCC-3′ and the reverse was 5′-
CATGTGGGCCATGAGGTCCACCAC-3′; the amplicon size is 322 bp).
Immunoblotting
Protein extraction was performed on ice using total protein extraction buffer: 50 mM Hepes
pH 7.5, 150 mM NaCl, 20% SDS, 1 mM EDTA, 1 mM EGTA, 10% Glycerol, 1% Triton,
25 mM NaF, 10 μM ZnCl2, 50 mM DTT. Before lysis, Protease Inhibitor Cocktail 1/200
(Sigma, P8340), 500 μM PMSF, 1 mM Sodium Orthovanadate and 1 mM β-
Glycerophosphate were added. Protein concentration was measured using a BCA Protein
Assay Kit (Pierce Biotechnology). Protein samples (80 μg) were denatured at 95°C and
subsequently separated by 12.5% SDS-PAGE gel electrophoresis. After transfer to
nitrocellulose membrane and blocking with BSA 1%, samples were probed with the home-
Gilabert et al. Page 4
J Cell Physiol. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
made VMP1 rabbit polyclonal antibody (Ropolo et al., 2007), grp78 and CHOP rabbit
polyclonal antibodies (Santa Cruz Biotechnology), LC3 rabbit polyclonal antibodies (Cell
Signaling), p62 mouse monoclonal antibody (BD Bioscience) and β-tubulin (Sigma) using
SNAP i.d.i.e. protein detection system (Millipore).
Establishment of VMP1/EGFP-inducible MiaPaCa2 cells
pVgRXR and pIND plasmids were obtained from Invitrogen. The VMP1/EGFP cDNA
(Dusetti et al., 2002) was cloned into the pIND vector to obtain the pIND-VMP1/EGFP
vector. MiaPaCa2 cells were transfected with 10 μg of pVgRXR vector, which contains the
ecdysone nuclear receptor subunit. Clones were selected and tested for Ponasterone A
(PonA, Invitrogen) responsiveness by transient transfection with pIND-VMP/EGFP reporter
plasmid. Clones showing moderate expression were transfected with 10 μg of the pIND-
VMP1/EGFP vector and selected in zeocin (0.4 mg/ml) and G418 (0.4 mg/ml). MiaPaCa2
clones were tested for VMP1-inducible expression after PonA (10 mM) treatment by
epifluorescence of the EGFP-fused protein. These double resistant clones were picked to
generate a stable cell line expressing pVgRXR and pIND-VMP1/EGFP and were cultured in
the presence of zeocin (0.05 mg/ml) and G418 (0.2 mg/ml) (VMP1/EGFP-inducible
MiaPaCa2 cells). The addition of PonA 10 mM to the culture medium induces formation of
the RXR/VgEcR heterodimer, which binds the hybrid ecdysone response element in the
pIND vector and activates the expression of VMP1/EGFP.
Transient transfection
p_empty, p_VMP1 and p_VMP1ΔBBD plasmids were previously reported (Ropolo et al.,
2007). Transfection efficiency was more than 80% as judged by expression of the EGFP-
fusion protein. Sixteen hours after transfection, 10,000 cells/well were plated in 96 well
plates and 16 hours later cells were treated with the anticancer drugs Rapamycin (10 μM),
Adriamycin (10 μM), Staurosporin (0.5 μM), Imatinib (0.3 μM), Cisplatin (125 μm) and
with hypoxia (0.2%) for 24 h and cell survival was estimated as described above.
In vivo tumor generation
Mouse PonA-inducible model: Sixty days delayed release pellets with PonA or vehicle
(Innovative Research of America) were implanted subcutaneous in male BALB/c athymic
nude mice 4–6 weeks old with a metal trocar. Implants were introduced one day before
subcutaneous injection of VMP1/EGFP-inducible MiaPaCa2 cells. Subcutaneous tumors
were induced in nude mice by injection of 5 × 106 inducible MiaPaCa2 cells in DMEM 10%
FBS. Gemcitabine was administered intraperitonealy once every 3 days at 65 mg/kg.
Tumors were measured with external caliper and volume was calculated as (4π/3) ×
(width/2) 2 × (length/2) as previously described (Gironella et al., 2007).
Ki-67 immunostaining
Slides were deparaffinized, hydrated, and placed in antigen retrieval citrate buffer (pH 6.0;
Dako North America) in a pressure cooker for 15 minutes. For Ki-67 staining, slides were
blocked with avidin/biotin (Dako) for 10 minutes. Slides were then placed in 3% H2O2 for
10 minutes followed by incubation in protein block (Dako) for 15 minutes. Slides were
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stained with Ki-67 (mouse anti-rat, 1:50; Dako) for 1 h followed by incubation with the
secondary antibody and counterstaining. Ki-67-positive cells were counted in four random
fields (x400 magnification). All slides were counted independently by two investigators
blinded to the treatment groups.
Patients and Tissue Microarray (TMA)
PDAC samples were formalin fixed surgical specimens obtained from the Pathology
Department of the Aix Marseille University. Tumors were diagnosed and classified
according to Klöppel and colleagues criteria (Luttges et al., 2000). Briefly, well
differentiated tumors have well or moderately differentiated duct-like structures and tubular
glands, mucin production, less than 10 mitosis per 10 HPFs and little to moderate nuclear
polymorphism, whereas poor differentiated tumors are characterized by the presence of
poorly differentiated glands with mucoepidermoid and pleomorphic structures, without
mucin production, more than 10 mitosis per 10 HPFs, and with marked nuclear
polymorphism and increased size. Histopathological grade was confirmed in all cases by
two experienced pathologists (SG and VS). The procedure for construction of TMAs was as
previously described (Charpin et al., 2012; Giusiano et al., 2011; Giusiano et al., 2010).
Briefly, cores were punched from the selected paraffin blocks and distributed in new blocks,
with two cores of 0.6 mm diameter for each tumor. TMA serial tissue sections were
prepared 24 hours before immunohistochemical processing and stored at 4°C. The
immunoperoxidase procedures were performed using an automated Ventana Benchmark XT
autostainer. Measurements of immunoprecipitates densitometry in cores were assessed in
individual core after digitization and “cropping” of microscopic images as previously
reported (Charpin et al., 2012; Giusiano et al., 2011; Giusiano et al., 2010). Polyclonal rabbit
antiserum to VMP1 against the peptide MAQSYAKRIQQRLNSEEKTK (residues 386–406)
was obtained as previously reported (Ropolo et al., 2007) and used at 1:500 dilution.
Specificity of the antibody was previously described (Grasso et al., 2011).
Statistics
Statistical analyses were performed using the Student t-test. All values were expressed as
mean ± SEM, with significance set at p≤0.05. qRT-PCR data are representative of at least 3
independent experiments repeated at least two times in each case. For VMP1 protein
expression on TMA, the statistical test used was GLM (General Linear Mixed) model with
contrast statement to test differences among the 4 population (SAS Institute Inc., Cary, NC,
USA).
Results
VMP1 is upregulated in human pancreatic cancer to participate in the response of
pancreatic tumor cells to hypoxia and chemotherapeutic drug
We examined the localization and expression of the VMP1 protein in human pancreatic
cancer by IHC on a TMA containing 88 primary PDAC, 23 metastasis and 26 normal
peritumoral tissues. Figure 1 shows that, in normal peri-tumoral pancreatic tissue, VMP1
protein is expressed at low levels in acinar cells (except for rare cases of isolated cells;
Figure 1A, arrows). On the other hand, an increase in VMP1 expression was systematically
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detected in PDAC and in metastasis samples. To better characterize this phenomenon, we
quantified the levels of VMP1 in relationship to the differentiation state of the tumors by
classifying our samples into well-differentiated, poor differentiated and metastatic tumors.
This analysis reveal a significant difference between peri-tumoral and well differentiated,
poor differentiated and metastasis samples (p>0.001) as well as between well differentiated
and poor differentiated (p>0.03). However, no significant differences were found between
well differentiated or poor differentiated tumors with metastasis (Figure 1B). Altogether
these data suggest that VMP1 expression is induced in PDAC, associated to the poor
prognosis of the tissues examined, and thus may likely modify the response of these tumors
to treatment. To test this idea, we therefore treated MiaPaCa2 cells with anticancer drugs,
including Rapamycin (10 μM), Gemcitabine (100 μM), Adriamycin (10 μM), Staurosporin
(0.5 μM), Imatinib (0.3 μM), Cisplatin (125 μm). Parallel experiments involved exposing
these cells to hypoxia (0.2% O2) for 24 h. The results of these experiments, shown in Figure
2 demonstrate that similar to the direct inducers of ER stress tested above, Rapamycin,
Adriamycin, Cisplatin and hypoxia upregulated VMP1 expression. On the other hand,
Gemcitabine, Staurosporin and Imatinib downregulated VMP1 expression (Figure 2). Thus,
combined these experiments reveal that several ER stressors, which bear significance
relevance to pancreatic cancer, induce VMP1. Our results also show that VMP1 induction
shows certain level of selectivity to a subset of chemotherapeutic drugs. Thus, we
subsequently, investigated the role of VMP1 in the chemotherapeutic response by these
drugs, by evaluating the effect of knocking down VMP1 on the resistance of pancreatic cells
to Imatinib, Cisplatin, Adriamycin, Staurosporin and Rapamycin in three tumoral cell lines,
namely MiaPaCa2, Panc1 and HeLa cells. We observed that siVMP1 transfection (see
Figure 2B) do not showed a significant effect on cell survival in the absence of any other
treatment. However, Figure 3 demonstrate that RNAi-mediated downregulation of VMP1
decreases the cell resistance against all these treatments (Figure 3). Similar results were
obtained with a second siRNA sequence against VMP1 (data not shown). Thus, congruent
with the experiments shown above in Figure 1, 2 and 3, this data support the notion that
VMP1 is upregulated in response to both hypoxia and to widely used chemotherapeutic
drugs likely to support the development of resistance to these treatments.
VMP1 behaves as a gene modifier of the response to Gemcitabine treatment in preclinical
models of pancreatic cancer
The in vitro experiments described above suggest a potential for VMP1 to act as a gene
modifier of the pancreatic tumor cells response to chemotherapeutic treatment, particular in
the subset of tumor that show a poor prognosis. Since Gemcitabine is the drug of choice for
this type of tumors, we evaluated the antitumor effect of this drug in relationship to VMP1
expression. For this purpose, we developed a xenograft system using MiaPaCa2 cells
engineered to express a PonA inducible VMP1/EGFP protein. Mice were treated with PonA
or with placebo and randomly selected for treatment with either Gemcitabine or saline
solution as control. Gemcitabine was administrated intraperitoneally once every 3 days for 5
consecutive weeks, starting after 1 week from the subcutaneous injection of the pancreatic
tumoral cells. Figure 4 shows that VMP1 expressing tumors grew more than the placebo-
treated counterpart (1365 ± 122 vs. 964 ± 119 mm3). Most notably, while Gemcitabine had a
significant effect on saline-treated tumors (1021 ± 112 vs. 224 ± 39 mm3), this effect was
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almost abolished in PonA-treated cells. In addition, immunohistochemical analysis of
MiaPaCa2 tumor sections stained with Ki-67 to measure proliferation index showed a
significant increase in Ki-67 staining in the PonA-treated tumors in both, treated and
untreated with Gemcitabine (Figure 4B and C). Altogether, our results reveal that enhanced
expression of VMP1, which we know occurs in human pancreatic tumors from clinical
series (Figure 4), modify the response to the widely used agent Gemcitabine. This data must
be taken into consideration for evaluating VMP1 as either a potential target or a marker that
modifies the sensitivity to of pancreatic cancer to chemotherapeutic treatment.
VMP1 modifies the response to chemotherapeutic agents independently of its role in cell
growth regulation or autophagy
We evaluated whether the chemotherapeutic effects of VMP1 occur through the
modification of either cell growth or autophagy. Since cell growth represent, in large part, a
balance between cell proliferation and apoptosis we measured Brdu incorporation and
caspase 3/7 activity in VMP1/EGFP-inducible MiaPaCa2 cells. No significant differences
were obtained in both cell growths as estimated by cell counting none by measuring BrdU
incorporation (supplementary Figure 1). Moreover, no differences were observed in caspase
3/7 activity (supplementary Figure 1). Thus, over-expression of VMP1 alone, as showed in
Figure 2C), neither affects cell growth nor death in vitro. Nonetheless, in light of the results
obtained with chemothepeutic drugs in vitro, it remain possible that enhanced levels of
VMP1 modify cell growth under conditions in which pancreatic tumors cells are exposed to
these agents. Indeed, the results of additional experiments using this type of agents show
that VMP1 expression significantly increased cell viability after either hypoxia or treatment
with single chemotherapeutic agents, namely Imatinib, Cisplatin, Adriamycin, Staurosporin
or Rapamycin (Figure 5A). Thus, VMP1 appears to modulate pancreatic cell growth only in
response to treatment. Due to the biomedical relevance of these results, we evaluated
whether the effects of VMP1 as a modifier of chemotherapeutic responses can be accounted
by its well-established cellular function, namely the regulation of autophagy. Consequently,
we induced VMP1 expression with PonA while inhibiting autophagy flux by treating the
cells either chemically (chloroquin 10 μM) or genetically through the RNAi-based inhibition
of two well-known autophagy regulators such as siATG5 (see Figure 5A and C) and
siBeclin1 (data not shown). Unexpectedly, we found that the protective effect of VMP1
against chemotherapeutic agents largely occurs independent of autophagy. These novel
autophagy-independent effects of VMP1 were confirmed using a mutated VMP1ΔBBD
construct carrying a deletion in its C-terminal BBD (Beclin 1 binding domain), which is
crucial for its autophagy function (Ropolo et al., 2007). Figure 5B demonstrates that
transfection of either VMP1 wild type or VMP1ΔBBD construct resulted in similar protective
effect when MiaPaCa2 cells were treated by hypoxia, Imatinib, Cisplatin, Adriamycin,
Staurosporin or Rapamycin. Thus, we conclude that the protective effects that enhanced
expression of VMP1 have on chemotherapeutic drugs occurs independent of a direct role in
either cell growth regulation or autophagy.
VMP1 functions in the ATF6-dependent ER stress response
Recently, elegant studies have demonstrated that response of the pancreas to ER stress is a
defining feature of both pancreatic cancer and pancreatitis. ER stress has also been
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established as an important mechanism underlying the response of pancreatic tumors to
chemotherapy. Thus, since VMP1 is an important player in these pancreatic diseases and, as
shown here, this protein modifies the response to this type of drugs, we evaluated its
mechanistic role in ER stress. Accordingly, we induced ER stress in MiaPaCa2 cells by the
treatment with Tunicamycin (3 μg/ml), Brefeldin A (5 μ/ml), Thapsigargin (500 nM) or
Dithiothereitol (1 mM) for 24 h and measured the expression of VMP1, grp78 and CHOP by
both qRT-PCR and Western blotting. Indeed, we find that VMP1 mRNA and protein
expression were induced by these ER stress inducer treatments (Figure 6). Notably, VMP1
upregulation coincided with the expression of grp78, an unfolded protein response
chaperone, and CHOP, an ER stress induced gene, which levels were also enhanced in
response to the treatments (Figure 6). Similarly, expression of the VMP1 mRNA was
induced by the treatments in Panc1 and BxPC-3 human pancreatic cancer cells (data not
shown). Combined these results, lead us to investigate whether the regulation of VMP1, is
mediated by known ER stress pathways such as ATF6 and ATF4 (Kim et al., 2006). RNAi-
based experiments, demonstrate that downregulation of ATF6 does not induce change the
levels of VMP1 mRNA in MiaPaCa2 cells. Notably, however, when ER stress was induced,
VMP1 expression significantly decreased in siATF6-treated cells, indicating that VMP1
activation is mediated by this protein (Figure 6). In contrast, RNAi-based ATF4 knocking
down did not induced changes in VMP1 mRNA expression either in untreated or in cells
undergoing ER stress (data not shown). These results links, for the first time, the induction
of VMP1 to the ATF-dependent ER response with selectivity for the ATF6 isoform. Thus,
VMP1 appears to plays a wider role in regulating the function of intracellular membranous
organelles, which like autophagy and ER stress, play a significant role in the pathobiology
of pancreatic cancer.
Discussion
In this paper we report that the autophagy-associated protein VMP1 is induced by some ER
stress inducing factors through the ATF6 transcription factor, by hypoxia and by some, but
not all, antitumoral agents. We also find that VMP1 knocking down increases, whereas its
forced over-expression decreases, the sensitivity to all tested antitumoral agents in an
autophagy-independent manner. Finally, we demonstrated that VMP1 is overexpressed in
PDAC, particularly in the poorly differentiated forms.
Several targeted therapies that have been tested in PDAC have not been successful in
eradicating the disease nor in improving significantly overall survival. Possible reasons for
such failure are the strong resistance of PDAC cells to chemotherapy and radiotherapy
(Wong and Lemoine, 2009) and the presence of an extensive fibrotic stroma, which is
believed to favor rapid tumor progression and to create a physical barrier against drug
delivery and immune cell infiltration (Olive et al., 2009; Provenzano et al., 2012). Besides a
very abundant stroma, PDAC histology is characterized by poor vascularization, indicating
that pancreatic cancer cells must adapt to an unfavorable microenvironment, which is both
nutrient and oxygen poor. The limited supply of oxygen and nutrients likely to underlie the
rigorous selection of cells that will ultimately form the tumor. In fact, pancreatic cancer
resistant cells activate a complex genetic program to resist to the stress induced by that
adverse environment. Therefore, a key strategy for increasing the effect of treatment against
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PDAC could be to block the action of the stress factors activated in the PDAC. We
speculated that VMP1 could be one of these factors because its expression in the pancreas is
dependent of the ER stress and hypoxia as showed in Figures 2 and 6. The results presented
in this paper support this notion since knocking down VMP1 decreases resistance to
anticancer drugs while overexpression of this protein has the opposite effect.
Since VMP1 activation has been largely associated, although not exclusively, to autophagy
(Calvo-Garrido and Escalante, 2010; Grasso et al., 2011; Itakura and Mizushima, 2010;
Ropolo et al., 2007; Tian et al., 2010; Vaccaro et al., 2008), which may play a role in
pancreatic cancer cell resistance (Grasso et al., 2012), we speculate that VMP1 could protect
the cell by activating ER stress-, hypoxia- and antitumoral drugs-dependent autophagy. To
our surprise, although VMP1 over-expression readily induces autophagy (Figure 2) in
PDAC-derived cells as expected, the protective effect was not dependent of autophagy since
blocking the autophagy flux by using chloroquin or siRNA against autophagy-dependent
factors ATG5 and Beclin1, or by transfecting a Beclin 1 binding domain deficient form of
VMP1, did not significantly influenced its protective effect (Figure 5). In other words, the
protective effect of VMP1 against anti-tumoral drugs remains almost intact in these
conditions. Because drugs used have very different intracellular targets, we presume that
VMP1 defensive effect is based on the activation of a general, yet undetermined, defensive
program. Another interesting point is that VMP1 is expressed in PDAC and it is associated
with their poor prognosis. One possible explanation is that, as showed in Figure 4, its over-
expression increases the resistance to the first line of treatment Gemcitabine. However,
because tumoral growth was more important in tumors expressing high levels of VMP1
(Figure 4), independently of any treatment, we cannot exclude an additional yet unknown
effect on cancer progression.
Expression of several stress proteins is activated in pancreatic as well as no pancreatic
cancer cells and their effect is almost systematically associated to a protective effect,
decreased sensitivity to cell death by anti-tumoral drugs and/or to cancer progression and
metastasis (Cano and Iovanna, 2010). These stress proteins include heat shock proteins
(Baylot et al., 2011; Song et al., 2008; Xia et al., 2012a; Xia et al., 2009; Xia et al., 2012b)
but not exclusively (Feldman et al., 2005; Sandi et al., 2011; Walsh et al., 2011). Overall,
our data, together with observations from other laboratories, support the hypothesis that
stress-associated genes could be efficient targets to treat patients with PDAC.
In summary, the current study demonstrates that VMP1 levels are increased in human
pancreatic tumors with poor prognosis. Enhanced VMP1 levels modify the response of
pancreatic tumoral cells to well-known chemotherapeutic drugs both in vitro and in vivo.
Mechanistically, we find that the role of VMP1 in this response occurs independently of
direct effects of this protein either on cell growth, apoptosis, or autophagy. Additionally,
functional experiments reveal for the first time that VMP1 participates in these phenomena,
at least in part, through its novel role in the ER stress response. The participation of VMP1
in ER stress shows a defined selectivity for the ATF6 pathway. Together, these results not
only identify a critical role for VMP1 in pancreatic cancer but also outline novel molecular
mechanisms underlying it function. Finally, VMP1 could be a new therapeutic target to
treating patients with a PDAC.
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Figure 1. Expression of VMP1 in PDAC
VMP1 protein expression by IHC on a TMA containing 88 primary PDAC, 23 metastasis
and 26 normal peritumoral tissues. Representative samples of peritumoral pancreas, well
differentiated PDAC, poor differentiated and metastasis (A). Measurements of
immunoprecipitates densitometry in cores was assessed as described in Material and
Methods section. Values were represented in a box-and-whisker diagram. Statistical
differences between groups were indicated (B).
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Figure 2. VMP1 is induced by anticancer drugs and hypoxia
MiaPaCa2 cells were treated with the anticancer drugs Rapamycin (10 μM), Gemcitabine
(100 μM), Adriamycin (10 μM), Staurosporin (0.5 μM), Imatinib (0.3 μM), Cisplatin (125
μm) and with hypoxia (0.2%) for 24 h and VMP1 mRNA expression was measured by qRT-
PCR (A). All values were expressed as mean ± SEM, with significance set at p≤0.05. qRT-
PCR data are representative of at least 3 independent experiments repeated at least two times
in each case. MiaPaCa2, Panc1 and HeLa cells were transfected with siVMP1 and
expression of its target was monitored using qRT-PCR (B). VMP1/EGFP-inducible
MiaPaCa2 cell expresses detectable levels of VMP1/EGFP fusion protein in response to the
PonA treatment (C). VMP1/EGFP-inducible MiaPaCa2 cell were treated with PonA alone
or together with chloroquin for 24 hours. LC3, p62 and β-tubulin amounts were measured by
western blot (D).
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Figure 3. VMP1 knocking down sensitizes to hypoxia and anticancer drugs effects
MiaPaCa2, Panc1 and HeLa cells were transfected with siVMP1 or siCtrl and 24 h later
treated with the anticancer drugs Rapamycin (10 μM), Gemcitabine (100 μM), Adriamycin
(10 μM), Staurosporin (0.5 μM), Imatinib (0.3 μM), Cisplatin (125 μm) and with hypoxia
(0.2%). Cell survival analysis was performed using Countess™ cell counter (Invitrogen) on
three independent samples for each condition. Data are means of triplicates ± SEM.
Statistically different from siCtrl-treated control (* p≤0.05).
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Figure 4. VMP1 over-expression increases resistance to Gemcitabine treatment in vivo
Release pellets with PonA or vehicle were implanted subcutaneously in athymic nude mice
4–6 weeks old. Twenty hours later, subcutaneous tumors were induced in nude mice by
injection of 5 × 106 VMP1 inducible MiaPaCa2 cells. Gemcitabine or saline was
administered intraperitonealy once every 3 days at 65 mg/kg and tumor growth was
measured with external caliper. Data are means of n=6 animal per group ± SEM.
Statistically differences from PonA and placebo were indicated (A). Ki-67 staining. The
percentage of Ki-67-positive cells was determined in four random fields (400x) for placebo
and PonA-treated tumors with or without Gemcitabine (B). Representative tumors are
shown (C); Tumors from animals treated with PonA show a significant increase in tumor
cell proliferation in both, treated and untreated with Gemcitabine.
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Figure 5. VMP1 over-expression protects from hypoxia and anticancer drugs effects
independently of its autophagic-associated effect
(A) VMP1/EGFP-inducible MiaPaCa2 cells were treated with PonA or placebo, alone or in
combination with chloroquin or siATG5, and 24 h later treated with the anticancer drugs
Imatinib (0.3 μM), Cisplatin (125 μm), Adriamycin (10 μM), Staurosporin (0.5 μM),
Rapamycin (10 μM) and with hypoxia (0.2%). (B) MiaPaCa2 cells were transfected with p-
empty, VMP1 or VMP1ΔBBD plasmids and treated by hypoxia, Imatinib, Cisplatin,
Adriamycin, Staurosporin and Rapamycin es described above for 24 h. Cell survival
analysis was performed using Countess™ cell counter (Invitrogen) on three independent
samples for each condition. Data are means of triplicates ± SEM. Statistically different from
siCtrl-treated control (* p≤0.05). (C) MiaPaCa2 cells were transfected with siATG5 and
expression of its target was monitored using qRT-PCR.
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Figure 6. VMP1 is induced by endoplasmic reticulum stressors
MiaPaCa2 cells were treated with Tunicamycin (3 μg/ml), Brefeldin A (5 μ/ml),
Thapsigargin (500 nM) or Dithiothereitol (1 mM) for 24 h and the expression of VMP1,
grp78 and CHOP was determined by qRT-PCR (A, B and C) and Western blotting (D). (E)
MiaPaCa2 cells were transfected with siCtrl or siATF6 and 24 later treated with the
endoplasmic reticulum stressor for an additional 24 h period and the expression of VMP1
was determined by qRT-PCR. All values were expressed as mean ± SEM, with significance
set at p≤0.05. qRT-PCR data are representative of at least 3 independent experiments
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repeated at least two times in each case. (F) MiaPaCa2 cells were transfected with siATF6
and expression of its target was monitored using qRT-PCR.
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